Category: AtriCure Inc.Syndicate content

AtriCure renews outlook on another strong quarter

July 25, 2014 by Arezu Sarvestani

AtriCure gets some Wall Street love after again boosting its full-year expectations on the back of a 30% boost in revenues in its 2nd quarter.

AtriCure renews outlook on another strong quarter

Ohio-based AtriCure (NSDQ:ATRC) gained a few points today as investors reacted to new of the company's Q2 financial report.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

AtriCure tops Q1 sales estimates, raises 2014 outlook

April 28, 2014 by Brad Perriello

AtriCure's 1st-quarter sales rise 28% and beat expectations on Wall Street, prompting it to boost its revenue guidance for the rest of the year.

AtriCure tops Q1 sales estimates, raises 2014 outlook

AtriCure (NSDQ:ATRC) boosted its 1st quarter sales above Wall Street's forecast, posting nearly 28% growth, and raised its outlook on revenues for the rest of the year.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

AtriCure's Q4 prelims send shares up

January 10, 2014 by Brad Perriello

AtriCure's report of strong sales growth for the 4th quarter and 2013 sends share prices up on Wall Street.

AtriCure's Q4 prelims send shares up

Fresh off of the $34 million acquisition of Estech, AtriCure (NSDQ:ATRC) reported strong sales growth for the 4th quarter and 2013 and predicted even better gains for this year, sending share prices up today on Wall Street.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

AtriCure acquires Estech's ablation systems in $34M deal

January 3, 2014 by Chris Walker

AtriCure offers $34 million up-front in stock for surgical ablation devices maker Estech, with another $26 million tied to performance-based milestones.

AtriCure acquires Estech in $34M deal

AtriCure (NSDQ:ATRC) signed a definitive agreement with Estech, offering to give the ablation devices maker about $34 million in stock.

AtriCure wins FDA nod for anti-stroke device trial

November 19, 2013 by Brad Perriello

AtriCure says the FDA granted an investigational device exemption for a clinical trial of its AtriClip left atrial appendage exclusion device to gauge its utility in preventing stroke in patients with atrial fibrillation.

AtriCure wins FDA nod for anti-stroke device trial

AtriCure (NSDQ:ATRC) said today that the FDA approved the launch of a clinical trial to examine whether its AtriClip device can be used to prevent strokes in patients with atrial fibrillation.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

AtriCure gains on surging Q3 sales, raised outlook

October 30, 2013 by Brad Perriello

AtriCure shares are up today after the medical device company reported surging 3rd-quarter sales and raised its outlook for the rest of the year.

AtriCure gains on surging Q3 sales, raised outlook

AtriCure (NSDQ:ATRC) shares added more than 8% today after the medical device company reported 3r-quarter sales that beat Wall Street's forecast and raised its outlook for the rest of the year.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp